1743-P: Assessing Disparities in Diabetes Prevention and Obesity Pharmacotherapy Treatment Outcomes among Veterans—A Local Cohort Study

Résumé fourni par la source

Introduction and Objective: Obesity and related complications, like diabetes, disproportionally affect minority groups in the U.S. and among Veterans. Despite effective anti-obesity medications (AOMs), disparities in access, prescriptions, and treatment responses persist. We evaluated differences in weight loss and glycemic control across racial and ethnic groups using various AOMs in our local clinic. Methods: We conducted a retrospective analysis on 180 patients treated at a local weight management clinic between 2019-2023, with up to 1 year of follow-up. Two-way ANOVA was used to analyze changes in weight and HbA1c across each racial and ethnic group and by prescription. Results: The cohort was predominantly male (75%) with mean age of 51 years, and similar proportions of Hispanic, Black, and Caucasian patients. The average BMI was 37.7 kg/m2 and mean HbA1c was 6.2%, with 34% having type 2 diabetes and 44% prediabetes. Black males exhibited more severe obesity and higher rates of prediabetes, while Hispanic males showed lower obesity but higher diabetes prevalence. Most patients were prescribed a single AOM, most commonly metformin followed by liraglutide and semaglutide. Weight loss with metformin was less pronounced among Hispanics compared to Caucasians (-0.6 ± 0.5 vs -1.9 ± 0.7 lb/month, p=0.04), while liraglutide and semaglutide produced significant weight loss but no difference across groups. Glycemic responses also varied; Blacks showed smaller HbA1c reductions with metformin, but semaglutide improved HbA1c consistently across all racial groups. Conclusion: Our findings highlight racial and ethnic disparities in AOM responses, suggesting the need for tailored treatment approaches to optimize weight management and glycemic control outcomes. Disclosure D. Torres Pinzon: None. J. Mathew: None. J. Vasquez Mendez: None. J. Pendse: None. M. Santacatterina: None. J.O. Alemán: Consultant; Novo Nordisk. Funding American Diabetes Association New York Regional Center for Diabetes Translational Research; New York University - TULA Saul J. Farber Health Equity Award

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.